Scott Adams, creator of Dilbert, went public asking President Trump for help getting access to Pluvicto, a targeted radioligand therapy for advanced prostate cancer, after facing scheduling delays with his health provider. The story touches on how the drug works, its FDA approval, practical limits like supply and handling, patient side effects, and a debate over medical bureaucracy versus rapid access to life-prolonging treatments. This article breaks down the treatment, the practical hurdles Adams encountered, and why prompt action matters for fast-moving cases of metastatic prostate cancer.
Adams, 67, revealed his diagnosis and said his cancer no longer responds to standard therapies. He made a direct appeal in public, explaining the situation and asking for help to speed up treatment scheduling. That public plea brought attention to both the drug and the system that delayed his infusion.
“My healthcare provider, Kaiser of Northern California, has approved my application to receive a newly FDA-approved drug called Pluvicto,” Adams wrote in the post. “But they have dropped the ball in scheduling the brief IV to administer it and I can’t seem to fix that.” Those lines captured a common frustration: authorization is one thing, timely delivery is another.
“I am declining fast. I will ask President Trump if he can get Kaiser of Northern California to respond and schedule it for Monday. That will give me a fighting chance to stick around on this planet a little bit longer.” Trump replied publicly with “On it!” and that exchange highlights how political figures can become unexpected intermediaries when the system stalls. From a conservative viewpoint it’s a call for accountability and quick action, not spectacle.
Kaiser issued a statement saying in part, “Mr. Adams’ oncology team is working closely with him on the next steps in his cancer care, which are already underway. Since it was approved by the FDA three years ago, Kaiser Permanente’s nuclear medicine and medical oncology experts have treated more than 150 patients with Lu-177 PSMA (Pluvicto) in Northern California alone. We know this drug and this disease.” That response aims to reassure people that care teams are engaged even when scheduling hiccups occur.
Pluvicto, made by Novartis, contains lutetium Lu 177 vipivotide tetraxetan and is a radioligand therapy that aims radiation directly at prostate cancer cells. Dr. Alan Bryce described it bluntly: “It involves a radioactive isotope, which has been linked to a targeting molecule that delivers the isotope to prostate cancer cells.” The precision approach is designed to hit tumors while sparing healthy tissue.
“In this way, it has the advantage of concentrating the active drug at the site of the cancerous tissue and delivering less of the drug to healthy tissues.” That targeted action often reduces systemic side effects compared with chemotherapy and can relieve symptoms while extending survival for some patients. Doctors view it as a valuable additional tool in an oncologist’s toolkit.
Pluvicto was approved in 2022 for specific metastatic castration resistant prostate cancer patients and later expanded to people able to delay chemotherapy. The treatment is typically given by IV every six weeks for as many as six doses, depending on response and tolerance. Availability can be limited because each dose must be made for a particular patient and handled in special facilities.
Supply and logistics have been a factor; initial manufacturing challenges created shortages that have since eased. Pluvicto must be prepared and delivered carefully because the isotope decays over time, so clinics need proper infrastructure to administer it safely. That infrastructure gap explains why some areas may not offer the therapy on short notice.
Common side effects include fatigue, dry mouth, nausea, back pain, joint pain, decreased appetite and constipation, and lab changes can occur that require monitoring. Rare but serious risks include bleeding, infections like sepsis, kidney injury and pulmonary embolism, and the drug should not be used during pregnancy. As Dr. Marc Siegel pointed out, “Chemo has more systemic side effects, because Pluvicto is targeted at affected tissue only.”
For patients like Adams, timing is crucial: delays can cost precious weeks. The clash here is clear—medical innovation exists and can extend life, but getting those treatments to patients fast enough requires nimble systems and accountability. Political attention can speed the process, but the long-term solution is stronger local capacity and clearer pathways to access when time matters most.
